Why do most c-erbB-2/HER-2-positive breast cancer patients fail to respond to Herceptin?

被引：0
|
作者：
Murphy, M. L. [1 ]
Chan, S. K. W. [1 ]
Bazley, L. [1 ]
Hayes, N. V. L. [1 ]
Gullick, W. J. [1 ]
机构：
[1] Univ Kent, Dept Biosci, Canterbury, Kent, England
来源：
BREAST CANCER RESEARCH | 2006年 / 8卷 / Suppl 2期
关键词：
Epidermal Growth Factor Receptor; Breast Cancer Patient; Human Epidermal Growth Factor Receptor; Humanize Monoclonal Antibody; Herceptin;
D O I：
10.1186/bcr1590
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S16 / S17
页数：2
相关论文
共 50 条
  • [41] Herceptin as Standard for Patients with HER2-positive Breast Cancer Benefit of subcutaneous Application
    Karger, S.
    BREAST CARE, 2019, 14 (04) : I - II
  • [42] The role of c-erbB-2 as a predictive factor in breast cancer
    Yamauchi H.
    Stearns V.
    Hayes D.F.
    Breast Cancer, 2001, 8 (3) : 171 - 183
  • [43] Overexpression of c-erbB-2 protein and locoregional recurrence in node-positive breast cancer
    Stal, O
    Klintenberg, C
    Sullivan, S
    BREAST, 1997, 6 (06): : 354 - 360
  • [44] Prevalence of Cardiotoxicity Secondary to Trastuzumab in Patients with HER-2-Positive Breast Cancer in Southeast Mexico
    Pascual-Mathey, Luz I.
    Velez-Figueroa, Midory I.
    Diaz-Vallejo, Joel J.
    Mendez-Hirata, Gustavo
    Mendez-Machado, Gustavo F.
    REPORTS, 2024, 7 (03)
  • [45] Bortezomib (PS-341, Velcade) increases the efficacy of trastuzumab (Herceptin) in HER-2-positive breast cancer cells in a synergistic manner
    Cardoso, Fatima
    Durbecq, Virginie
    Laes, Jean-Francois
    Badran, Bassam
    Lagneaux, Laurence
    Bex, Francoise
    Desmedt, Christine
    Willard-Gallo, Karen
    Ross, Jeffrey S.
    Burny, Arsene
    Piccart, Martine
    Sotiriou, Christos
    MOLECULAR CANCER THERAPEUTICS, 2006, 5 (12) : 3042 - 3051
  • [46] Adjuvant trastuzumab: A milestone in the treatment of HER-2-positive early breast cancer
    Baselga, Jose
    Perez, Edith A.
    Pienkowski, Tadeusz
    Bell, Richard
    ONCOLOGIST, 2006, 11 : 4 - 12
  • [47] THE HER2 (C-ERBB-2) ONCOGENE IS FREQUENTLY AMPLIFIED IN INSITU CARCINOMAS OF THE BREAST
    LIU, E
    THOR, A
    HE, M
    BARCOS, M
    LJUNG, BM
    BENZ, C
    ONCOGENE, 1992, 7 (05) : 1027 - 1032
  • [48] PTEN key to herceptin response in Her2-positive breast cancer
    不详
    CANCER BIOLOGY & THERAPY, 2004, 3 (09) : 796 - 796
  • [49] Neratinib in HER-2-positive breast cancer: results to date and clinical usefulness
    Chan, Arlene
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2016, 8 (05) : 339 - 350
  • [50] C-ERBB-2 AND HUMAN CANCER
    PASTAN, I
    JAPANESE JOURNAL OF CANCER RESEARCH, 1993, 84 (12): : 1336 - 1337
12345